Abstract

Continuous-flow left ventricular assist devices (CF LVAD) are increasingly used in the therapeutic algorithm for patients with end-stage heart failure (HF). Treated patients show improvements on global health status measures. However, there has been limited investigation regarding the prevalence and

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call